Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5

Lysosomotropic agents such as sunitinib, lapatinib, and chloroquine belong to a drug family that is being used more frequently to treat advanced cancers. Sunitinib is standard care for metastatic renal cell carcinomas (mRCC) and lapatinib is used for trastuzumab/pertuzumab-refractory cancers. Howeve...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Theranostics
Auteurs principaux: Giuliano, Sandy, Dufies, Maeva, Ndiaye, Papa Diogop, Viotti, Julien, Borchiellini, Delphine, Parola, Julien, Vial, Valérie, Cormerais, Yann, Ohanna, Mickaël, Imbert, Véronique, Chamorey, Emmanuel, Rioux-Leclercq, Nathalie, Savina, Ariel, Ferrero, Jean-Marc, Mograbi, Baharia, Pagès, Gilles
Format: Artigo
Langue:Inglês
Publié: Ivyspring International Publisher 2019
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6401402/
https://ncbi.nlm.nih.gov/pubmed/30867824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.29093
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires